The effect of dexmedetomidine on vasopressor requirements in patients with septic shock: a subgroup analysis of the Sedation Practice in Intensive Care Evaluation [SPICE III] Trial

Table 3 Multivariable adjusted analysis of the association between hourly dexmedetomidine dose and noradrenaline equivalent to MAP ratio (NEq/MAP)

Effect	Estimate	Standard error	p value
Dexmedetomidine, per μg/kg/h increase	− 0.165	0.071	0.02
Age, per year increase	− 0.003	0.003	0.38
Baseline log NEq/MAP, per unit increase	0.312	0.059	< 0.001
Location
Switzerland	− 0.672	0.101	< 0.001
Australia	0
No hydrocortisone	0.134	0.108	0.22
hydrocortisone	0
No CRRT	− 0.635	0.105	< 0.001
CRRT	0
No liver cirrhosis	− 1.371	0.247	< 0.001
Liver cirrhosis	0
No portal hypertension	− 0.477	0.174	0.008
Portal hypertension	0
APACHE III admission diagnosis
Cardiovascular	0.678	0.272	0.02
Gastrointestinal	0.186	0.125	0.14
Hematological	0.091	0.696	0.90
Musculoskeletal	− 0.286	0.365	0.44
Renal	2.399	0.317	< 0.001
Respiratory	0.086	0.111	0.44
Sepsis	0

Adjusted for admission diagnosis, hospital site, baseline NEq/MAP ratio, continuous renal replacement therapy, age, administration of hydrocortisone, and presence of liver cirrhosis
APACHE Acute Physiology And Chronic Health Evaluation, CRRT continuous renal replacement therapy, MAP mean arterial pressure, NEq noradrenaline equivalents, NEq/MAP noradrenaline equivalents to MAP ratio (a higher ratio indicates higher vasopressor need to maintain a certain MAP)

ISSN: 1364-8535